Search Within

Hematologic Malignancies Research

Formats
  1. Journal Article (1545)
  2. Meeting Abstract (1260)
  3. Review (76)
  4. Editorial (35)
  5. Book Section (32)
  6. Research Letter (26)
  7. Conference Paper (15)
  8. Correspondence (8)
  9. Guidelines (4)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3005)
  2. GSK Faculty (2450)
  3. Department of Medicine (2318)
  4. Hematologic Malignancies, Division of (2120)
  5. Sloan Kettering Institute Faculty (2052)
  6. Molecular Pharmacology and Chemistry Program Faculty (1632)

More Groups

People
  1. Michel Sadelain (586)
  2. David Scheinberg (502)
  3. Alexander Lesokhin (381)
  4. Carl Landgren (336)
  5. Renier Brentjens (286)
  6. Gabriela Chiosis (281)

More People

Years
  1. 2025 (64)
  2. 2024 (131)
  3. 2023 (175)
  4. 2022 (126)
  5. 2021 (154)
  6. 2020 (173)

More Years

Publications
  1. Blood (660)
  2. Cancer Research (117)
  3. Journal of Clinical Oncology (112)
  4. Clinical Lymphoma, Myeloma and Leukemia (84)
  5. Biology of Blood and Marrow Transplantation (80)
  6. Molecular Therapy (68)

More Publications

Publishers
  1. American Society of Hematology (700)
  2. Nature Publishing Group (375)
  3. Elsevier Inc. (291)
  4. American Association for Cancer Research (245)
  5. American Society of Clinical Oncology (116)
  6. Cell Press (116)

More Publishers

Results (3005)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Inhibition of the cell cycle regulated Cdc7 kinase pathway is an efficacious therapeutic approach for hematologic malignancies and solid tumors
    Meeting Abstract

    Santos, R.; Shum, D.; Carrillo, D.; Zhang, R.; Churchill, M.; Mukherjee, S.; Brentjens, R.; Radu, C.; Kelly, T. J.; Djaballah, H.; more...
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Kluger, H.; Sznol, M.; Callahan, M.; Postow, M.; Gordon, R.; Segal, N. H.; Rizvi, N.; Lesokhin, A.; Atkins, M. B.; Kirkwood, J.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Auxiliar treatment by targeting the extracellular matrix to improve drug delivery and therapeutic response
    Meeting Abstract

    Henke, E.; Roehrig, F.; Hoffmann, H.; Escorcia, F.; Wartenberg, M.; Volova, S.; Gaetzner, S.; Rosenwald, A.; Erguen, S.; Scheinberg, D. A.; more...
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • Hsp90 pharmacoproteomics: Harnessing pieiotropy for therapeutic synergy
    Meeting Abstract

    Goldstein, R.; Chiosis, G.; Cerchietti, L. C.; Melnick, A. M.
    European Journal of Cancer (2014)

    Fulltext@MSK | Save
  • The Warburg effect confers adverse outcome in chronic lymphocytic leukemia
    Meeting Abstract

    Gardner, J. R.; Devlin, S. M.; Knapp, K.; Bauli, F.; Patel, M.; Lamanna, N.; Frattini, M. G.; Brentjens, R.; Maslak, P.; Jurcic, J. G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2014)

    Fulltext@MSK | Save
  • The road to treating smoldering multiple myeloma
    Conference Paper

    Korde, N.; Mailankody, S.; Landgren, O.
    Elsevier Inc. (2014)

    Fulltext@MSK | Save
  • Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion
    Journal Article

    Zhang, J.; Fan, J.; Venneti, S.; Cross, J. R.; Takagi, T.; Bhinder, B.; Djaballah, H.; Kanai, M.; Cheng, E. H.; Judkins, A. R.; more...
    Molecular Cell (2014)

    Fulltext@MSK | Save
  • CALGB 150905 (Alliance): Rituximab broadens the antilymphoma response by activating unlicensed NK cells
    Journal Article

    Du, J.; Lopez-Verges, S.; Pitcher, B. N.; Johnson, J.; Jung, S. H.; Zhou, L. L.; Hsu, K.; Czuczman, M. S.; Cheson, B.; Kaplan, L.; more...
    Cancer Immunology Research (2014)

    Fulltext@MSK | Save
  • Phenotypic and functional activation of hyporesponsive KIR(neg)NKG2A(neg) human NK-cell precursors requires IL12p70 provided by poly(I:C)-matured monocyte-derived dendritic cells
    Journal Article

    Curran, S. A.; Romano, E.; Kennedy, M. G.; Hsu, K. C.; Young, J. W.
    Cancer Immunology Research (2014)

    Fulltext@MSK | Save
  • A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas
    Journal Article

    Venneti, S.; Santi, M.; Felicella, M. M.; Yarilin, D.; Phillips, J. J.; Sullivan, L. M.; Martinez, D.; Perry, A.; Lewis, P. W.; Thompson, C. B.; more...
    Acta Neuropathologica (2014)

    Fulltext@MSK | Save